Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Boundless Bio, Inc. Common Stock (BOLD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: BOLD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.09% | Avg. Invested days 5 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.52M USD | Price to earnings Ratio 0.15 | 1Y Target Price 4 |
Price to earnings Ratio 0.15 | 1Y Target Price 4 | ||
Volume (30-day avg) 3 | Beta - | 52 Weeks Range 1.00 - 4.72 | Updated Date 07/17/2025 |
52 Weeks Range 1.00 - 4.72 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 7.71 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -29.89% | Return on Equity (TTM) -54.06% |
Valuation
Trailing PE 0.15 | Forward PE - | Enterprise Value -64159404 | Price to Sales(TTM) - |
Enterprise Value -64159404 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 22385600 | Shares Floating 14281523 |
Shares Outstanding 22385600 | Shares Floating 14281523 | ||
Percent Insiders 11.39 | Percent Institutions 70.35 |
Upturn AI SWOT
Boundless Bio, Inc. Common Stock
Company Overview
History and Background
Boundless Bio, Inc. is a clinical-stage oncology company dedicated to revolutionizing cancer treatment through inhibition of extrachromosomal DNA (ecDNA). It was founded in 2018 and went public in 2024.
Core Business Areas
- Oncology Drug Development: Focused on discovering and developing novel therapeutics that target ecDNA biology in cancer.
Leadership and Structure
The leadership team comprises experienced individuals in oncology drug development and corporate management. The organizational structure is typical of a biotech company, with research, development, and commercial functions.
Top Products and Market Share
Key Offerings
- BBI-355: A novel, oral inhibitor of dihydroorotate dehydrogenase (DHODH) designed to selectively kill cancer cells harboring ecDNA. Currently in Phase 1/2 clinical trials. Competitors developing similar therapies include companies focused on novel oncology targets and DHODH inhibitors, though none specifically targeting ecDNA.
Market Dynamics
Industry Overview
The oncology drug development industry is highly competitive and rapidly evolving, with a significant unmet need for therapies targeting previously intractable cancers.
Positioning
Boundless Bio is positioned as a pioneer in the ecDNA-targeted therapy space, with a unique approach to addressing cancer driver genes found on ecDNA.
Total Addressable Market (TAM)
The TAM for oncology therapies is estimated in the hundreds of billions of dollars annually. Boundless Bio's success hinges on its ability to effectively target ecDNA in a subset of cancers, potentially capturing a significant portion of this TAM. Market reports estimate the oncology market at $200 billion+ USD.
Upturn SWOT Analysis
Strengths
- First-mover advantage in ecDNA-targeted therapies
- Strong intellectual property position
- Experienced management team
- Novel approach to cancer treatment
Weaknesses
- Early-stage clinical development
- High cash burn rate
- Dependence on clinical trial success
- Relatively small company size
Opportunities
- Potential to address unmet needs in cancer treatment
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to other ecDNA-driven cancers
- Positive clinical trial data
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- MRNA
- LLY
- GILD
- AZN
Competitive Landscape
Boundless Bio is operating in a competitive landscape. Its competitive advantage lies in targeting ecDNA, but it faces competition from established oncology companies with broader pipelines and resources.
Growth Trajectory and Initiatives
Historical Growth: N/A - Relatively new company.
Future Projections: Future growth is heavily dependent on the success of BBI-355 and other pipeline candidates. Analyst estimates will likely emerge after more clinical data becomes available.
Recent Initiatives: Advancing BBI-355 through Phase 1/2 clinical trials, expanding research and development efforts.
Summary
Boundless Bio is a high-risk, high-reward biotech company pioneering a novel approach to cancer treatment. Its success hinges on clinical trial outcomes and securing further funding. Early data shows some promise, but competition from larger pharmaceutical companies is a significant risk. Positive clinical data should substantially increase the stock's value, whereas negative data may jeopardize its future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Boundless Bio's website
- SEC filings
- ClinicalTrials.gov
- Analyst reports (where available)
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investing in biotech companies involves significant risks. Market share values are approximate estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Boundless Bio, Inc. Common Stock
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2024-03-28 | CEO, President & Director Mr. Zachary Hornby | ||
Sector Healthcare | Industry Biotechnology | Full time employees 64 | Website https://boundlessbio.com |
Full time employees 64 | Website https://boundlessbio.com | ||
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company's lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. It also develops BBI-098, a picomolar biochemical inhibition of checkpoint kinase 1 demonstrating central nervous system penetrance in preclinical models. In addition, the company offers ECHO, an ecDNA harboring oncogenes diagnostic test to detect ecDNA in patient tumor specimens; and Spyglass platform, a platform used to identify druggable targets in oncogene amplified cancers. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.